[go: up one dir, main page]

WO2008042941A3 - Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse - Google Patents

Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse Download PDF

Info

Publication number
WO2008042941A3
WO2008042941A3 PCT/US2007/080270 US2007080270W WO2008042941A3 WO 2008042941 A3 WO2008042941 A3 WO 2008042941A3 US 2007080270 W US2007080270 W US 2007080270W WO 2008042941 A3 WO2008042941 A3 WO 2008042941A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasculogenesis
treatment
oncology
related disease
humanized anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/080270
Other languages
English (en)
Other versions
WO2008042941A2 (fr
Inventor
Melissa Damschroder
Acqua William Dall
Herren Wu
Emma T Bowden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of WO2008042941A2 publication Critical patent/WO2008042941A2/fr
Publication of WO2008042941A3 publication Critical patent/WO2008042941A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des versions humaines d'anticorps monoclonaux de souris anti-EphB4. L'invention concerne également des compositions pharmaceutiques, des compositions immunothérapeutiques et des procédés d'utilisation d'anticorps thérapeutiques qui se lient à l'antigène humain EphB4 et qui peuvent médier ADCC, CDC, et/ou l'apoptose du traitement de tumeurs malignes humaines et de pathologies et de maladies liées à la vasculogenèse.
PCT/US2007/080270 2006-10-04 2007-10-03 Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse Ceased WO2008042941A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82819006P 2006-10-04 2006-10-04
US60/828,190 2006-10-04

Publications (2)

Publication Number Publication Date
WO2008042941A2 WO2008042941A2 (fr) 2008-04-10
WO2008042941A3 true WO2008042941A3 (fr) 2008-12-11

Family

ID=39269178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080270 Ceased WO2008042941A2 (fr) 2006-10-04 2007-10-03 Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse

Country Status (1)

Country Link
WO (1) WO2008042941A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2137216A2 (fr) * 2007-03-12 2009-12-30 Vasgene Therapeutics, Inc. Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス, インコーポレイテッドVasgenetherapeutics, Inc. ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
WO2011127219A1 (fr) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Biomarqueurs circulants pour une maladie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719971B1 (en) * 1991-06-14 2004-04-13 Genentech, Inc. Method for making humanized antibodies
US20050249736A1 (en) * 2003-03-12 2005-11-10 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719971B1 (en) * 1991-06-14 2004-04-13 Genentech, Inc. Method for making humanized antibodies
US20050249736A1 (en) * 2003-03-12 2005-11-10 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
WO2008042941A2 (fr) 2008-04-10

Similar Documents

Publication Publication Date Title
NL301196I2 (nl) inebilizumab
WO2006089133A3 (fr) Anticorps anti-cd19 et leur utilisation en oncologie
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2006121852A3 (fr) Traitements des maladies auto-immunes par anticorps anti-cd19
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2006099875A8 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MY149630A (en) Antibodies against amyloid-beta peptide
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
WO2010005566A3 (fr) Agents de liaison de notch et antagonistes de notch ainsi que procédés d'utilisation correspondants
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
MX2009013656A (es) Composiciones terapeuticas anti-cd20 y metodos.
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
EP4467648A3 (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
WO2008066691A3 (fr) Tes7, et anticorps se liant à celui-ci
WO2008105886A3 (fr) Anticorps spécifiques fcgriib humanisés, et leurs procédés d'utilisation
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
WO2008100563A3 (fr) Compositions et méthodes pour diagnostiquer et traiter le cancer
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
WO2008042941A3 (fr) Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse
WO2008152537A3 (fr) Anticorps monoclonaux humanisés dirigés contre le récepteur du facteur de croissance épidermique humain, leur utilisation, et procédé correspondant
CY1116887T1 (el) Anti-cd19 αντισωματα και χρησεις στην ογκολογια
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868359

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07868359

Country of ref document: EP

Kind code of ref document: A2